Notably, it has been reported that PD-L1-expressing FDCS exhibits a good response to immune checkpoint therapy, suggesting that dendritic cell neoplasms should be managed according to PD-L1 status for optimal clinical benefit [158]. This evidence concerns the gene CD274 and dendritic cell tumor.